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Abstract
Ichthyosis vulgaris is a common genetic skin disorder characterized by dry, scaly skin. About 1% of
the European population have the full presentation of ichthyosis vulgaris; up to 10% have a milder,
subclinical form. Atopic eczema is the most common, inflammatory skin condition, affecting 20% of
children. It is often accompanied by a number of other allergies, including atopic asthma. Atopic
eczema is a complex trait, where predisposing genes in combination with environmental stimuli
produce the disease. Recently, we reported the first loss-of-function genetic mutations in the filaggrin
gene as the cause of ichthyosis vulgaris. We noted people with ichthyosis vulgaris also have atopic
eczema (and vice versa) and that the filaggrin gene sits in a known atopic eczema susceptibility locus.
We went on to confirm that filaggrin mutations, carried by up to 10% of the population, are the
major genetic predisposing factor for atopic eczema and the various allergies associated with atopic
eczema. Filaggrin is a highly abundant protein expressed in the uppermost part of the epidermis that
is critical to the formation and hydration of the stratum corneum—the outermost dead cell layers
responsible for the barrier function of the skin. Filaggrin deficiency leads to a “leaky” skin barrier that
allows higher than normal water loss (explaining the dry, scaly skin), as well as allowing entry of
allergens through the epidermis where they trigger inflammatory and allergic immune responses
(atopic eczema and allergies). This work has placed the skin barrier at the center stage of eczema and
allergy research and has kick-started new therapy development programs aimed at repairing or
enhancing skin-barrier function as a means of treating or preventing these very common diseases.
It was a tense Friday afternoon in October 2005. Four of
us in the lab had been working furiously that week in the
fear that our results would bescoopedatany moment. (It
was an unfounded worry, but we had no way of knowing
that at the time.) We had recently found the first
mutation in a gene associated with a relatively common
skin disease, but our results didn’t fully make sense, and
we suspected there must be a second mutation hidden in
this gene. A second mutation might explain the strange
genetic patterns we had seen in affected families, and it
also seemed to hint at a much bigger story.
A few months previously, we had started sequencing the
gene encoding filaggrin—a gigantic protein expressed in
large quantities in the outermost layers of the epidermis.
The sequence of the filaggrin gene (FLG) was one of the
last to be completed by the Human Genome Project, and
for good reason—it is an unusually large and repetitive
gene, making sequence analysis very difficult. To
sequence it once was an effort that took years; to do it
repeatedly, as we would have to for our mutational
screens, was much more challenging. After months of
perseverance and perspiration, Frances Smith, a senior
research fellow in the lab, had managed to design a
method to sequence one part of the gene.This allowed us
to identify a single nonsense mutation in some of our
patients with ichthyosis vulgaris, a hereditary disorder
characterized by severe flaking of the skin.
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others had been trying to sequence this gene for years.
Beverly Dale and colleagues at the University of Washing-
ton in Seattle had identified the filaggrin protein in the
1980s and had sought its sequence, but there was a lot of
contradictory information regarding its role in ichthyosis
vulgaris.Threemajorlaboratorieshadthrowntheirweight
behind the sequencing effort, but with no success.
Part of the reason for the difficulty was that filaggrin is
made in the form of a monster precursor protein called
profilaggrin, which has a molecular weight of more than
400,000 Da—eight to nine times more massive than
most proteins. That in itself wasn’t the problem from the
standpoint of genetic analysis, but the structure of the
gene is also unusual. The mRNA is huge, about 13,000
bases, almost all of which are encoded by a single exon.
Unruly as the gene was, the real challenge was that the
protein is a polymer made of 10 or more identical
subunits with the same protein sequence. Therefore,
within that big exon there are one-kilobase blocks of
sequence that are roughly identical, arranged in a line,
one after the other. That’s where the real problem lay.
When researchers tried to replicate a particular segment
of the gene using a PCR (polymerase chain reaction)
technique, the primers that mark the start and end of the
DNA sequence were not specific enough to distinguish
one segment of the polymeric gene from another. So
when researchers tried to sequence the gene and look for
mutations, it was never clear whether they were sequen-
cing a unique region of the gene, or one of the other nine
regions simultaneously. It was as if nature was having a
joke at our expense.
My lab started to sequence FLG, the filaggrin gene, in
American, Scottish, and Irish families suffering from
ichthyosis vulgaris. Frances Smith and I had learned a
few sequencing tricks from cloning another large,
repetitive gene back in the mid-1990s, so when we
started working on filaggrin, we found the first mutation
fairly quickly, right at the start of this massive gene. Just
as the literature had predicted, this mutation, which
completely stops filaggrin protein production, was
present in some, but not all, samples from patients
with ichthyosis vulgaris. But strangely enough, when we
looked at our “normal” controls, which should have
lacked the mutation, about 4–5% also carried the
defective gene. When my clinical collaborator, Alan
Irvine from Our Lady’s Children’s Hospital in Ireland,
took a closer look at patient records, he started to see a
pattern. Patients with ichthyosis seemed to suffer from
either a severe form or a mild form of the disease. In fact,
about one in ten of the normal population also
had ichthyosis, only it was such a mild, subclinical
version of the condition that it could be treated with skin
moisturizer to relieve the symptoms.
That’s when we started searching in earnest for a second
mutation. We figured that patients with a mutation on
onealleleofthegenewouldstillhaveasecondgoodcopy
of the gene on their other allele, producing filaggrin, just
less of it, and explaining the mild form of the disease. A
second mutation would knock out both copies of the
gene, explaining the more severe cases. We had generated
a large 12,000-base-pair PCR fragment containing one
copy of the mutation from an American patient with
severe ichthyosis, and we assumed the patient’s other
allele would carry a second mutation. We cloned the PCR
fragments, and sequenced a clone lacking the first
mutation. We didn’t have primers that would sequence
it fully, so we simply threw a whole bunch of sequencing
primers at this clone, and as luck would have it, one of
them landed near the second mutation. On that fateful
Friday afternoon, we saw the first hint of the second
mutation. By Saturday afternoon, after an overnight
experiment, we had already validated it [1].
That mayhave been enough to start celebrating, but there
was more riding on the finding than just this one rare
disease.When Alan went backoverhispatientrecords, he
noticed that ichthyosis vulgaris sufferers also exhibited
another, very common, skin disease—eczema—much
more frequently than the general population. I pulled
togethereveryoneinthelabonMonday,holdingasortof
emergency meeting of the war cabinet, to discuss the
possibility that we had not just one but two really huge
stories. “Whatever you’re doing,” I told them, “put it to
bed—everyone works on this for the next couple of
months.” It was a once-in-a-lifetime opportunity.
There was a chance that this enormous, bizarre skin
protein not only was responsible for flaky skin, but could
offer a new genetic and cellular explanation for eczema
[2], as well as for other common allergies.
The hunt
I had thought about filaggrin for years. As a postdoc in
Birgit Lane’s lab in Dundee back in 1995, I had worked
on a similarly large and clunky skin protein called
plectin. The protein contained six repeated regions,
each of which had additional small internal repeats.
This fractal-like gene, with a large 7000-base-pair
exon, was unlike anything I’d ever tried to clone. It was
the great white whale of my postdoctoral work. We’d
come into the lab every few days with a new idea for
how to get at it, building a sizable toolbox of
techniques and tricks that we used to finally elucidate
the plectin gene’s sequence.
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toral work, which involved genetic disorders of keratin
genes. Keratins form the filamentous cytoskeleton within
epithelial cells of the epidermis. The stacked sheets of
cells forming the skin’s outermost layer function as a
protective barrier between the organism and its environ-
ment. Epithelial cells gain their mechanical strength from
this tough keratin cytoskeleton in their cytoplasm, and
defects in keratin genes make the skin more fragile. In the
case of the epidermal keratins, this manifests as skin
blistering in response to trauma as mild as rubbing, often
accompanied by overgrowth and thickening of the skin,
as the epidermis tries in vain to compensate for the
fragility of the cells. Some 23 of the 54 keratin genes are
known to be linked to various human genetic diseases.
After working on keratin genes for a number of years, we
went on to characterize and sequence genes encoding
proteins such as plectin that either bind to keratins and
anchor the cytoskeleton to membranes, or that modify
the keratins, giving epithelial cells a plethora of proper-
ties, from elasticity to hardness and water resistance. One
of these proteins, filaggrin, was similar in complexity to
plectin. Given the strong hints that it might be involved
in ichthyosis vulgaris, by the mid-1990s I was just itching
to try to sequence its gene and look for disease-causing
mutations. But the gene was off limits. I considered
Beverly Dale and colleagues at Seattle (who had initially
identified the protein) friendly rivals, and I knew that her
lab was working out FLG’s sequence. We liked those guys
a lot. It was their gene, so we decided not to pursue it.
Normal skin (left): In the granular layer of normal skin, the large profilaggrin protein is dephosphorylated and enzymatically cut into 10–12 smaller filaggrin
molecules (1). As these cells move up to form the stratum corneum, they flatten their shape by collapsing their keratin structure—a process aided by
interaction with filaggrin proteins (2). In the stratum corneum, filaggrin degrades into amino acids essential for maintaining moisture in the outer layers of skin
(3). The intact skin barrier of healthy skin keeps allergens, pathogens (bacteria and viruses) and chemical irritants out of the body (4).
Eczema (right): Mutations in the filaggrin gene greatly reduce the amount of filaggrin protein in the skin or lead to its complete absence (1), resulting in
cracks in the skin barrier (2) that expose the lower layers to allergens which are usually kept out, thus causing eczema (3). Once foreign material, such as an
allergen, passes through the defective skin barrier, it is spotted by cells of the immune system, leading to inflammation of the skin and other allergic responses
(4). If a child is exposed to allergens through the skin, that exposure is more likely to prime the immune system to react aggressively to that allergen lateri n
life, explaining the coincidence of asthma and eczema seen in patients throughout the world.
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met one of Beverly’s colleagues, dermatologist Phil
Fleckman. On the bus ride back from a social gathering
near Park City, we started chatting about filaggrin. In the
intervening years, a number of labs had had a go at
sequencing filaggrin, but all had given up. Maybe it was
finally our turn to try it. Phil sent us their DNA samples,
and a few months later we had the first mutation, with
the second mutation close on its tail.
When looking at the patient records for different varieties
of ichthyosis vulgaris, Alan noticed that the patients had
frequently also been diagnosed with atopic eczema, the
most common skin disease. Atopic (or allergic) eczema
affects aboutone in five childrenin industrializednations.
It is an inflammatory skin condition, usually starting in
infancy or early childhood, with symptoms of red,
inflamed, and intensely itchy skin. Eczema is very often
accompanied by a plethora of allergies, including food
and pet allergies, asthma, and hay fever.
Immediately, we went to the literature and found a 2001
study by Bill Cookson and his colleagues, now at
Imperial College London. They had shown that there
was an eczema susceptibility locus on chromosome 1.
We scanned that locus in the human genome database—
it was a very large area—and the filaggrin gene was bang-
smack in the middle of it!
We went back to our DNA sample collection from
about 50 Irish ichthyosis vulgaris patients and 200
members of the general population. It was a really tiny
sample size for a case-control study. Most such genetic
epidemiological studies for complex traits would have
cases and controls that numbered in the thousands, so
we weren’t too hopeful about seeing a statistically
significant link to eczema. We counted the number of
people with a filaggrin mutation in the eczema patient
group and in the general population, and compared
the results using a statistical test. If the mutations were
significantly more common in patients with eczema
compared to the control group, then we had found an
eczema gene. A significant difference between the cases
a n dc o n t r o l si sm e a s u r e db yap value of 0.05 or lower.
In complex-trait genetics at that time, you considered
yourself lucky if you had something like 0.001. So we
were totally blown away when the statistical result
from our relatively small study came back as 10
-17!
This meant we had unbelievably strong evidence that
the filaggrin gene was involved in eczema. From our
more recent studies, we have shown that up to 50% of
children with moderate to severe eczema carry one or
two mutations in the filaggrin gene [3].
A neighboring lab in Dundee, headed by Colin Palmer,
had an ongoing study of the genetics of asthma. We
analyzed their samples of 600 school kids from Dundee,
Scotland, all of whom had asthma, as well as 1000
random population controls, for the two filaggrin muta-
tions. When we sorted the kids that had both eczema and
asthma from those with just asthma, the population
divided into two groups of almost exactly 300 children
each. Kids with asthma alone showed no association with
the filaggrin mutations, but children with both diseases
again showed a powerful statistical association.
Thatonesimpleexperimentshowedthatatthemolecular
level there aretwotypesof asthma:an asthmadriven by a
skin-barrier deficiency or eczema mechanism, and an
asthma driven by a different mechanism. We published
our initial asthma findings along with the eczema work.
It was an unreal month-long rollercoaster ride. Six
months later we had figured out how to fully sequence
the filaggrin gene,and discoveredthat there are anumber
of common mutations in the gene that arose thousands
of years ago in early human populations, in addition to
many rare mutations that have arisen more recently. Not
only was there an association between the mutations in
the gene and disease in people of European descent, we
also found that there are specific combinations of rare
and common mutations in other, nonwhite population
groups—in Asia, for example—making filaggrin an
important eczema/allergy gene worldwide [4,5].
The genetic basis of allergies
What at first appeared to be a surprising association
began to make sense on a cellular and molecular level as
we continued to study the protein. Filaggrin is crucial for
the formation of the stratum corneum, the layer of dead
cells at the surface of the skin, and also for the hydration
of this crucial barrier layer. People who have mutations
in one or both copies of the filaggrin gene produce dry
and flaky skin that is permeable to allergens or chemical
irritants. When the barrier is broken, foreign material is
able to pass through these skin layers. We think that
childhood eczema—which usually first occurs within the
first few months of life—is an indication that foreign
pathogens and irritants have passed through an abnor-
mally porous skin layer, activating a strong allergic
immune response, and thus priming the body to react to
antigens that it would not normally encounter by this
route. Later in life, when the child’s immune system
comes into contact with those same allergens, perhaps
through the lungs, it reacts aggressively, causing the
inflammation in the lungs that results in shortness of
breath. In fact, many children with eczema have multiple
allergies to house dust, pet hair, and other substances.
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and asthma had been dominated by immunological
theories. The predominant hypothesis dictated that
these diseases were caused by some malfunction of the
immune system. Indeed, patients who suffer from both
eczema and asthma have an overactive T helper 2
(Th2) immune system, the arm of the adaptive
immune response that spurs immunoglobulin E (IgE)
antibody production against allergens. While Th2
cytokines are indeed present, we have shown that it’s
not a primary malfunction in the immune system, but
a genetic malfunction in the skin that initiates eczema
and, in some cases, asthma. Skin-barrier function is
now center stage in eczema research. It should be
noted, however, that filaggrin is not the only predis-
posing gene for eczema, and it is likely that others will
emerge, some of which are likely to involve immune
system malfunction.
Excited by these findings, we quizzed our colleagues
for information about other diseases that might
possibly be affected by filaggrin-gene mutations. The
next natural target was psoriasis, another disease
characterized by itchy, flaky, red patches of skin. We
found no association with any filaggrin mutation,
although it appears that a nearby gene is involved in
psoriasis susceptibility.
Curing a genetic allergy?
The question now is how to prevent eczema, asthma,
and allergies from occurring in patients with the
susceptibility mutations in their filaggrin gene. If it
were possible to find a cure for eczema in adults, could
we also cure asthma, or would it be too late, with the
immune system permanently primed against allergens?
I would argue that it might at least help. If the skin
barrier is not repaired, then the immune system will
constantly produce more antibodies in response to
allergens that continue to get past the barrier. Stopping
that assault may have some beneficial effects. The
alternate possibility is that we may need to prevent
eczema in young children before they become sensi-
tized. If the latter proves true, would it be sufficient to
curb eczema early in life, as the immune system
develops? These are all questions we are gearing up to
answer.
We’ve recently published work on a mouse model with a
mutation in the murine filaggrin gene that is highly
analogous to the human mutations. These mice have
many of the hallmarks of eczema, including elevated IgE
and Th2 cytokine responses, thus providing compelling
experimental evidence for the skin-barrier hypothesis.
The plan is to create a mouse model in which we can
switch the filaggrin gene on or off at will as the mouse
develops, to define the most efficacious period for
intervention to prevent eczema.
We’ve also started to look for ways to help the body
replace filaggrin at the cellular level. We are currently
searching small-molecule chemical libraries for new
classes of compounds that might induce skin cells to
produce more filaggrin protein. Results look promising,
and we are hopeful that in a few years’ time, new drugs or
creams that enhance skin-barrier function will be
available to treat these common diseases.
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